Results 111 to 120 of about 280,456 (250)

Low-density lipoprotein apheresis in a pediatric patient of familial hypercholesterolemia: Primi experientia from a tertiary care center in North India

Asian Journal of Transfusion Science, 2017
Familial hypercholesterolemia (FH) is an autosomal dominant disorder due to mutation of apolipoprotein-B receptor gene causing severe dyslipidemia. Lifestyle modification and medical treatment attenuate the disease progression, but as these fail to ...
Kanchan Dogra, Alpesh Goyal, Rajesh Khadgawat, Yashdeep Gupta, Diptiranjan Rout, Parag Prabhakar Fulzele, Rahul Chaurasia, Poonam Coshic, Kabita Chatterjee   +8 more
doaj   +1 more source

Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels

Clinical Research in Cardiology Supplements, 2019
Lipoprotein(a) (Lp(a)) is a genetic risk factor for cardiovascular disease (CVD) and is associated with the induction and sustaining of atherosclerotic cardiovascular diseases (ASCVD).
V. Schettler, C. L. Neumann, C. Peter, T. Zimmermann, U. Julius, B. Hohenstein, E. Roeseler, F. Heigl, P. Grützmacher, H. Blume, R. Klingel, A. Vogt, Scientific Board of Glar for the German Apheresis Working Group   +12 more
semanticscholar   +1 more source

[Low density lipoprotein apheresis].

Medicina (Kaunas, Lithuania), 2004
Increased blood cholesterol concentration is one of the main factors in ischemic heart disease, development of which is determined by atherosclerotic changes in coronary vessels. Diet and treatment with 3-hydroxi-3-metilglutaril coenzyme A (HMG-CoA) reductase inhibitors helps to reduce low density lipoprotein cholesterol (LDL-Ch) blood concentration up
Remigijus, Zaliūnas, Rimvydas, Slapikas, Olivija, Gustiene, Jonas, Siurkus, Eduardas, Vaitkus   +4 more
openaire   +1 more source

VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body

Scientific Reports, 2017
Only free drugs have been believed to be carried into tissues through active or passive transport. However, considering that lipoproteins function as carriers of serum lipids such as cholesterol and triglycerides, we hypothesized that lipoproteins can ...
Hideaki Yamamoto, Tappei Takada, Yoshihide Yamanashi, Masatsune Ogura, Yusuke Masuo, Mariko Harada-Shiba, Hiroshi Suzuki   +6 more
doaj   +1 more source

Heparin-Mediated Extracorporeal Low-Density Lipoprotein Precipitation Apheresis for Treating Peripheral Arterial Disease in Patients with Chronic Kidney Disease

Journal of Clinical Medicine
Patients with chronic kidney disease (CKD), particularly those with end-stage renal disease (ESRD), have a high prevalence of cardiovascular disease and peripheral arterial disease (PAD).
Stefania Rotella, Loreto Gesualdo, M. Fiorentino   +2 more
semanticscholar   +1 more source

Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. [PDF]

, 1992
Apo E plays an important role in plasma lipoprotein metabolism through its high affinity binding to cell surface LDL receptor. In the present study, we studied the effects of apo E on the atherogenic process in Watanabe heritable hyperlipidemic rabbits ...
Gotoda Takanari, Harada Kenji, Inoue Ikuo, Kawamura Masako, Kohzaki Kohichi, Shimada Masako, Shimano Hitoshi, Shiomi Masashi, Tsukada Toyohiro, Watanabe Yoshio, Watanabe Yoshiro, Yamada Nobuhiro, Yazaki Yoshio, 山田 信博   +13 more
core   +1 more source

Lipoprotein apheresis – More than just cholesterol reduction?

Atherosclerosis Supplements, 2013
Lipoprotein apheresis is a well-established extracorporeal treatment in modality of severe hyperlipoproteinemia. Besides the reduction of LDL cholesterol and modifications to physiology of lipoprotein and lipid metabolism, Lipoprotein apheresis may have crucial effects on many other atherogenic factors as vascular inflammation, rheology and gene ...
Neumann, Claas L., Schulz, Egbert G., Hagenah, Gerit C., Platzer, Ulf, Wieland, E., Schettler, Volker   +5 more
openaire   +3 more sources

Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia

Journal of Lipid Research, 1996
Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is, however, unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates,
K G Parhofer, P H Barrett, T Demant, W O Richter, P Schwandt   +4 more
doaj   +1 more source

Rheopheresis in vascular diseases [PDF]

, 2018
K
Baráth, Sándor, Diószegi, Ágnes, Módis, László, Németh, Norbert, Soltész, Pál, Somogyi, Viktória, Szalai, Eszter, Vass, Melinda   +7 more
core   +1 more source

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study. [PDF]

, 2016
We aimed to determine the association between autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well as markers of CV risk in the general population.
Antiochos, P., Bastardot, F., Hartley, O., Mach, F., Marques-Vidal, P., Montecucco, F., Pagano, S., Satta, N., Virzi, J., Vollenweider, P., Vuilleumier, N., Waeber, G.   +11 more
core   +2 more sources